MorphImmune
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Morphimmune was an early-stage biotechnology company developing targeted oncology therapeutics through its proprietary Targeted Effector platform, which selectively delivers payloads to diseased cells to reduce toxicity and increase efficacy. Founded on the research of scientific co-founder Philip S. Low, the Purdue University chemistry professor who previously founded Endocyte (acquired by Novartis for $2.1 billion), Morphimmune was led from March 2023 by CEO Clay Siegall, the former Seagen CEO. In June 2023 Immunome announced a definitive merger agreement to acquire Morphimmune via a reverse merger, accompanied by a $125 million private placement.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- New CEO and merger
Former Seagen CEO Clay Siegall takes the helm at Morphimmune in March 2023; in June 2023 Immunome announces a definitive merger agreement (reverse merger) to acquire Morphimmune with a $125 million PIPE investment.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.